Antisecretory Factor Glioblastoma Phase 2
Condition(s) studied
Investigational drug(s) / intervention(s)
Salovum: Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
Placebo egg yolk powder: Egg yolk powder derived from hen fed with normal feed.
Study summary
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Eligibility
Primary outcome measure(s)
- Overall survival — up to 12 months from primary surgery
Survival
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Skåne University Hospital | Lund | Sweden | Recruiting |
More Peter Siesjö trials in Sweden
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05669820 on ClinicalTrials.gov ↗ ← All trials in Sweden